Jeff E. Knight - 31 Dec 2023 Form 5 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
Chief Operating Officer
Signature
/s/ Marc Wilson, as attorney-in-fact
Issuer symbol
CRNX
Transactions as of
31 Dec 2023
Net transactions value
+$27,294
Form type
5
Filing time
12 Feb 2024, 16:32:37 UTC
Previous filing
17 Mar 2023
Next filing
06 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Other $13,347 +891 +2.6% $14.98 35,291 22 May 2023 Direct F1
transaction CRNX Common Stock Other $13,946 +931 +2.6% $14.98 36,222 20 Nov 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares purchased under Crinetics Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan in a transaction exempt from Section 16(b) pursuant to Rule 16b-3(c),